Authors : 1Hector Sumano , Luis Ocampo and Juan Azuara
Abstract: A multicentric blind-clinical study, gathering 240 dogs of different breeds, ages and both genders was carried out. All dogs were affected of either one or both these diseases: acute tracheobronchitis and pneumonia. The severity of the respiratory problem was further classified into three categories for each diagnosis (nine categories in all). Dogs were randomly assigned, using an incomplete block design, to one of four treatments to complete 20 patients per grade of respiratory disease or 60 patients per antibacterial. Bacteriological analysis of nasal swabs and respiratory secretions was carried out before treatment and 48 hours after the last injection of the corresponding antibacterial. Independently from classification of the disease, treatments were as follows: group CEA, with cefotaxime 20 mg kg-1 IM, bid; group CEO with cefalone-1 in tablets for oral administration 20 mg kg-1 tid; group ENR with enrofloxacin 10 mg kg-1 SQ sid and group CEIM with the cefalone-1 injected intramuscularly, at a dose of 10 mg kg-1 bid. Tolerance, defined as the absence of clinical adverse reactions and hematological changes, and clinical efficacy, assessed as the absence of clinical signs, were recorded. Overall efficacy was as follows: group CEA: 79.14%; group CEO:79.76%; group ENR: 70.83% and group CEIM:93.3%. The total mean number of days needed to clinical cure were: group CEA: 13.3 ; group CEO: 15.0; group ENR: 15.5, and group CEIM: 11.7. Cefalone-1, injected intramuscularly, stood out in this study as the best choice for bacterial respiratory diseases in dogs.
1Hector Sumano , Luis Ocampo and Juan Azuara , 2003. Clinical Efficacy of Cefalone-1 (A New Cefalosporin-Fluoroquinolone Antibacterial) in Dogs with Various Respiratory Bacterial Infections . Journal of Animal and Veterinary Advances, 2: 675-680.